Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells

Leukemia

Volumn 21, Issue 12, 2007, Pages 2485-2494

  Svensson, E ^a   Vidovic, K ^a   Lassen, C ^a   Richter, J ^a   Olofsson, T ^a   Fioretos, T ^a   Gullberg, U ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; ARSENIC TRIOXIDE; BCR ABL PROTEIN; ETOPOSIDE; HYBRID PROTEIN; IMATINIB; ISOPROTEIN; LIPOCORTIN 5; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRYPAN BLUE; WT1 PROTEIN;

APOPTOSIS; ARTICLE; CD34 SELECTION; CELL PROTECTION; CELL STRAIN K 562; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DEREGULATION; DRUG RESISTANCE; ENHANCER REGION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL; TRANSCRIPTION TERMINATION; UMBILICAL CORD BLOOD;

EID: 36348970549     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404924     Document Type: Article

References (55)

1. Lee SB, Haber DA. Wilms tumour and the WT1 gene. Exp Cell Res 2001; 264: 74-99.
2. Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: Functions in growth and differentiation. Gene 2001; 273: 141-161.
3. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509-520.
4. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GAP. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990; 343: 774-778.
5. Fraizer GC, Patmasiriwat P, Zhang X, Saunders GF. Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow. Blood 1995; 86: 4704-4706.
6. Baird PN, Simmons PJ. Expression of the Wilms'tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997; 25: 312-320.
7. Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L. The Wilms' tumor gene is expressed in a subset of CD34+ progenitdrs and downregulated early in the course of differentiation in vitro. Exp Hematol 1997; 25: 945-950.
8. Menssen HD, Renkl HJ, Entezami M, Thiel E. Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth. Blood 1997; 89: 3486-3487.
9. Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H et al. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol 2002; 116: 409-420.
10. Hosen N, Shirakata T, Nishida S, Yanagihara M, Tsuboi A, Kawakami M et al. The Wilms' tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis. Leukemia 2007; 21: 1783-1791.
11. King-Underwood L, Little S, Baker M, Clutterbuck R, Delassus S, Enver T et al. Wt1 is not essential for hematopoiesis in the mouse. Leuk Res 2005; 29: 803-872.
12. Alberta JA, Springett GM, Rayburn H, Natoli TA, Loring J, Kreidberg JA. Role of the WT1 lumor suppressor in murine hematopoiesis. Blood 2003; 101: 2570-2574.
13. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) inhuman leukemias. Leukemia 1992; 6: 405-409.
14. Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I. Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. Leukemia 1993; 7: 970-977.
15. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071-3079.
16. Menssen HD, Renkl HJ, kodeck U, Maurer J, Notter M, Schwartz S et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9: 1060-1067.
17. Tamaki H, Ogawa H, Inoue K, Soma T, Yamagami T, Miyake S et al Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia. Blood 1996; 88: 4396-4398.
18. Phelan SA, Lindberg C, Call KM. Wilms' tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells. Cell Growth Differ 1994; 5: 677-686.
19. Sekiya M, Adachi M, Hinoda Y, Imai K, Yachi A. Downregulation of Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cells. Blood 1994; 83: 1876-1882.
20. Inoue K, Tamaki H, Ogawa H, Oka Y, Soma T, Tatekawa T et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998; 91: 2969-2976.
21. Svedberg H, Chylicki K, Baldetorp B, Rauscher III FJ, Gullberg U. Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program. Oncogene 1998; 16: 925-932.
22. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Tamaki H, Oji Y et al. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res 1999; 23: 499-505.
23. Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S et al. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood 2006; 107: 3303-3312.
24. Cilloni D, Messa F, Gottardi E, Fava M, Arruga F, Defilippi I et al. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer 2004; 101: 979-988.
25. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172-183.
26. Svensson E, Eriksson H, Gekas C, Olofsson T, Richter J, Gullberg U. DNA-binding dependent and independent functions of WT1 protein during human hematopoiesis. Exp Cell Res 2005; 308: 211-221.
27. Kelly PF, Vandergriff J, Nathwani A, Nienhuis AW, Vanin EF. Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. Blood 2000; 96: 1206-1214.
28. Edvardsson L, Dykes J, Olsson ML, Olofsson T. Clonogenicity, gene expression and phenotype during neutrophil versus erythroid differentiation of cytokine-stimulated CD34+ human marrow cells in vitro. Br J Haematol 2004; 127: 451-463.
29. Ginzinger DG. Gene quantification using real-time quantitative PCR: An emerging technology hits the mainstream. Exp Hematol 2002; 30 503-512.
30. Hakansson P, Lassen C, Olofsson T, Baldetorp B, Karlsson A, Gullberg U et al. Establishment and phenotypic characterization of human U937 cells with inducible P210 BCR/ABL expression reveals upregulation of CEACAM1 (CD66a). Leukemia 2004; 18: 538-547.
31. Zhang X, Xing G, Fraizer GC, Saunders GF. Transactivation of an intronic hematopoietic-specific enhancer of the human Wilms' tumor 1 gene by GATA-1 and c-Myb. J Biol Chem 1997; 272: 29272-29280.
32. Wu Y, Fraizer GC, Saunders GF. GATA-1 transactivates the WT1 hematopoietic specific enhancer. J Biol Chem 1995; 270: 5944-5949.
33. Chalandon Y, Jiang X, Hazlewood G, Loutet S, Conneally E, Eaves A et al. Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming. Blood 2002; 99: 3197-3204.
34. Zhao RC, Jiang Y, Verfaillie CM. A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector. Blood 2001; 97: 2406-2412.
35. Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ, Smith PJ. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 1996; 12: 1005-1014.
36. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis. Blood 1996; 87: 2878-2884.
37. Ito K, Oji Y, Tatsumi N, Shimizu S, Kanai Y, Nakazawa T et al. Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene 2006; 25: 4217-4229.
38. Miller Jr WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893-3903.
39. Glienke W, Chow KU, Bauer N, Bergmann L. Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leuk Lymphoma 2006; 47: 1629-1638.
40. Fukumi S, Horiguchi-Yamada J, Nakada S, Nagai M, Ohno T, Yamada H. Differential responses of Bcl-2 family genes to etoposide in chronic myeloid leukemia K562 cells. Mol Cell Biochem 2000; 206: 43-50.
41. Floros KV, Thomadaki H, Florou D, Talieri M, Scorilas A. Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide. Ann NY Acad Sci 2006; 1090: 89-97.
42. Chalandon Y, Jiang X, Christ O, Loutet S, Thanopoulou E, Eaves A et al. BCR-ABL-transduced human cord blood cells produce abnormal populations in immunodeficient mice. Leukemia 2005; 19: 442-448.
43. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86: 726-736.
44. Stokoe D. The phosphoinositide 3-kinase pathway and cancer. Expert Rev Mol Med 2005; 7: 1-22.
45. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-365.
46. Tuna M, Chavez-Reyes A, Tari AM. HER2/neu increases the expression of Wilms Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells. Oncogene 2005; 24: 1648-1652.
47. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19: 2474-2488.
48. Fraizer GC, Wu YJ, Hewitt SM, Maity T, Ton CC, Huff V. Transcriptional regulation of the human Wilms' tumor gene (WT1). Cell type-specific enhancer and promiscuous promoter. J Biol Chem 1994; 269: 8892-8900.
49. Ray S, Lu Y, Kaufmann SH, Gustafson WC, Karp JE, Boldogh I et al. Genomic mechanisms of p210BCR-ABL signaling: Induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis. J Biol Chem 2004; 279: 35604-35615.
50. Zhao W, Kitidis C, Fleming MD, Lodish HF, Ghaffari S. Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/ AKT signaling pathway. Blood 2006; 107: 907-915.
51. Dame C, Kirschner KM, Bartz KV, Wallach T, Hussels CS, Scholz H. The Wilms' tumor suppressor, Wt1, is a transcriptional activator of the erythropoietin gene. Blood 2006; 107: 4282-4290.
52. Na IK, Kreuzer KA, Lupberger J, Dorken B, le Coutre P. RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML. Leuk Res 2005; 29: 343-345.
53. Mayo MW, Wang CY, Drouin SS, Madrid LV, Marshall AF, Reed JC et al. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 1999; 18: 3990-4003.
54. Carrington D, Algar E. Overexpression of murine WT1 +/+ and -/- isoforms has no effect on chemoresistance but delays differentiation in the K562 leukemia cell line. Leuk Res 2000; 24: 927-936.
55. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 2006; 103: 14907-14912.